PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22973308-4 2012 When divided according to treatment by oral hypoglycaemic agents (OHA) and insulin (IT), they reacted differently with respect to investigated associations: in the OHA"s TC and LDL-C correlated negatively with FT(4) and showed no association with FT(3), whereas, in the IT"s TC and LDL-C correlated positively with FT(3) and negatively with FT(4). 10-oxohexadecanoic acid 164-167 insulin Homo sapiens 75-82 22830956-11 2012 CONCLUSIONS: Addition of once-daily insulin detemir to patients with type 2 diabetes mellitus on OHA therapy resulted in few adverse events, significant improvements in glycaemic control, small reductions in weight and low rates of hypoglycaemia. 10-oxohexadecanoic acid 97-100 insulin Homo sapiens 36-43 25048394-1 2014 Some type 2 diabetic patients can maintain optimal glycemic control by oral hypoglycemic agents (OHA) after their uncontrolled hyperglycemia is corrected by a temporary introduction of insulin therapy. 10-oxohexadecanoic acid 97-100 insulin Homo sapiens 185-192 25048394-9 2014 In conclusion, 0- and 120-min data during an OGTT, or even 120-min data alone, in combination with diabetic duration, body mass index, and 2-h post meal glucose levels were useful in predicting the efficacy of OHA after intensive insulin therapy in Japanese type 2 diabetic patients. 10-oxohexadecanoic acid 210-213 insulin Homo sapiens 230-237 22028157-6 2011 Fasting and postprandial C-peptide, M0, and M1 levels were the only differences between those with OHA response and those with OHA failure among diabetic subjects with low body mass index, high blood glucose level, or long-standing diabetes. 10-oxohexadecanoic acid 99-102 insulin Homo sapiens 25-34 21458350-4 2011 RESULTS: The OHA-treated group had a higher mean total score (20 items), a higher mean total score for 16 negative items and a lower mean total score for four positive items than the insulin-treated group. 10-oxohexadecanoic acid 13-16 insulin Homo sapiens 183-190 21458350-6 2011 In addition, the proportion of participants who rated the four positive items as "agree" or "strongly agree" was lower in the OHA-treated group than in the insulin-treated group. 10-oxohexadecanoic acid 126-129 insulin Homo sapiens 156-163 17475531-11 2007 CONCLUSION: Long-term combination therapy with OHA and CSII with only basic manipulation and optimization of insulin doses exerted on basal rate or on boluses is feasible, effective and well accepted in type 2 diabetes. 10-oxohexadecanoic acid 47-50 insulin Homo sapiens 109-116 19890623-8 2010 A significant reduction in 24 h excretion rate of 8-iso-PGF2alpha from 126 (47-248) to 62 (35-111] pmol/mmol of creatinine was observed in the add-on insulin group (p = 0.005) but not in the add-on OHA group. 10-oxohexadecanoic acid 198-201 insulin Homo sapiens 150-157 20356473-10 2010 The patients treated with insulin (especially with CSII) had higher remission rates and better improvement of AIR at 1 year follow-up irrespective of the recruiting FPG (CSII or MDI vs OHA: 57.1%, 51.8% vs 32.8% in stratum A, P < 0.05; 44.4%, 38.7% vs 18.6% in stratum B, P < 0.05). 10-oxohexadecanoic acid 185-188 insulin Homo sapiens 26-33 15586391-6 2005 Diabetic subjects who were being treated with a combination of OHA and insulin (n = 53;25.6 +/- 11.5 ng/mL) had significantly (p = 0.0009) lower levels of TGFbeta1 when compared with those who were being treated with OHA alone (n = 48;34.1 +/- 13.4 ng/mL). 10-oxohexadecanoic acid 217-220 insulin Homo sapiens 71-78 17727695-12 2007 By the end of the 12-month study, 179 of the initially OHA-treated patients had started insulin injections; 186 of the patients already treated with insulin had increased their injections. 10-oxohexadecanoic acid 55-58 insulin Homo sapiens 88-95 17565917-2 2007 With the use of outcome data and patient characteristics reported from an ongoing prospective observational trial, a validated computer simulation model of diabetes was used to project the clinical and cost outcomes associated with therapy conversion to insulin detemir over a 35-y period from (1) OHA only, (2) neutral protamine Hagedorn insulin (NPH)+/-OHA, and (3) insulin glargine+/-OHA. 10-oxohexadecanoic acid 298-301 insulin Homo sapiens 254-261 17565917-5 2007 Treatment with insulin detemir+/-OHA was associated with increases in quality-adjusted life expectancy of 0.309, 0.350, and 0.333 quality-adjusted life-years (QALYs) versus treatment with OHA alone, NPH+/-OHA, and insulin glargine+/-OHA, respectively. 10-oxohexadecanoic acid 33-36 insulin Homo sapiens 15-22 17565917-5 2007 Treatment with insulin detemir+/-OHA was associated with increases in quality-adjusted life expectancy of 0.309, 0.350, and 0.333 quality-adjusted life-years (QALYs) versus treatment with OHA alone, NPH+/-OHA, and insulin glargine+/-OHA, respectively. 10-oxohexadecanoic acid 33-36 insulin Homo sapiens 214-221 17565917-8 2007 On the basis of preliminary evidence of short-term improvements in glycemic control and reduced hypoglycemia, therapy conversion to insulin detemir+/-OHA from OHA alone, NPH+/-OHA, or insulin glargine+/-OHA was projected to increase quality-adjusted life expectancy and to represent a cost-effective treatment option in the United States. 10-oxohexadecanoic acid 150-153 insulin Homo sapiens 132-139 17565917-8 2007 On the basis of preliminary evidence of short-term improvements in glycemic control and reduced hypoglycemia, therapy conversion to insulin detemir+/-OHA from OHA alone, NPH+/-OHA, or insulin glargine+/-OHA was projected to increase quality-adjusted life expectancy and to represent a cost-effective treatment option in the United States. 10-oxohexadecanoic acid 159-162 insulin Homo sapiens 132-139 17565917-8 2007 On the basis of preliminary evidence of short-term improvements in glycemic control and reduced hypoglycemia, therapy conversion to insulin detemir+/-OHA from OHA alone, NPH+/-OHA, or insulin glargine+/-OHA was projected to increase quality-adjusted life expectancy and to represent a cost-effective treatment option in the United States. 10-oxohexadecanoic acid 159-162 insulin Homo sapiens 132-139 17565917-8 2007 On the basis of preliminary evidence of short-term improvements in glycemic control and reduced hypoglycemia, therapy conversion to insulin detemir+/-OHA from OHA alone, NPH+/-OHA, or insulin glargine+/-OHA was projected to increase quality-adjusted life expectancy and to represent a cost-effective treatment option in the United States. 10-oxohexadecanoic acid 159-162 insulin Homo sapiens 132-139 9069587-6 1997 Patients treated with insulin therapy had a higher frequency of peripheral vascular disease (insulin therapy, 14%; OHA therapy, 10%; p < .05); neuropathy (insulin therapy, 55%; OHA therapy, 37%; p < .0001); and retinopathy (insulin therapy, 71%; OHA therapy, 45%; p < .0001). 10-oxohexadecanoic acid 115-118 insulin Homo sapiens 22-29 12174320-8 2002 After starting insulin, metabolic control may significantly improve in OHA-treated patients. 10-oxohexadecanoic acid 71-74 insulin Homo sapiens 15-22 11523910-7 2001 The fasting insulin of the OHA group was also greater than that of the diet group but was not statistically significant. 10-oxohexadecanoic acid 27-30 insulin Homo sapiens 12-19 12408284-3 2002 Regular insulin therapy is also indicated in patients of diabetes associated with renal or hepatic disease where OHA is contra-indicated. 10-oxohexadecanoic acid 113-116 insulin Homo sapiens 8-15 10332674-9 1999 Among those in the original and in the new cohorts who survived follow-up, respectively, OHA use decreased from 80 to 48% (P < 0.001) and from 67 to 50% (P < 0.003) and insulin use increased from 20 to 33% (P = 0.001) and from 33 to 37% (P = 0.603). 10-oxohexadecanoic acid 89-92 insulin Homo sapiens 175-182 9069587-6 1997 Patients treated with insulin therapy had a higher frequency of peripheral vascular disease (insulin therapy, 14%; OHA therapy, 10%; p < .05); neuropathy (insulin therapy, 55%; OHA therapy, 37%; p < .0001); and retinopathy (insulin therapy, 71%; OHA therapy, 45%; p < .0001). 10-oxohexadecanoic acid 180-183 insulin Homo sapiens 22-29 9069587-6 1997 Patients treated with insulin therapy had a higher frequency of peripheral vascular disease (insulin therapy, 14%; OHA therapy, 10%; p < .05); neuropathy (insulin therapy, 55%; OHA therapy, 37%; p < .0001); and retinopathy (insulin therapy, 71%; OHA therapy, 45%; p < .0001). 10-oxohexadecanoic acid 180-183 insulin Homo sapiens 22-29 9069587-9 1997 In a subgroup of individuals with diabetes duration > 10 years (n = 211 for insulin treatment, n = 118 for OHA treatment), the frequency of neuropathy still was significantly higher in the insulin group (63% vs 49%; p < .016) as was retinopathy (85% vs 58%; p < .0001). 10-oxohexadecanoic acid 110-113 insulin Homo sapiens 192-199 9288551-8 1997 These results demonstrate that complementary insulin therapy probably induces antiatherogenic lipoprotein changes in NIDDM patients previously treated by either OHA or INS 1-2x. 10-oxohexadecanoic acid 161-164 insulin Homo sapiens 45-52 1634193-8 1992 These results demonstrate that insulin treatment may restore insulin sensitivity in NIDDM patients resistant to OHA treatment and that after three years there is no exhaustion of B-cell function. 10-oxohexadecanoic acid 112-115 insulin Homo sapiens 31-38 8480059-7 1993 Older patients on treatment with insulin had longer duration of disease, less obesity, low level basal of C-Peptide and a low response to post glucagon C-Peptide (0.94 +/- 0.5 pmol/ml) compared with patients on diet (1.8 +/- 0.9 pmol/ml) and OHA (1.8 +/- 0.8 pmol/ml). 10-oxohexadecanoic acid 242-245 insulin Homo sapiens 33-40 2123183-10 1990 This study shows that addition of glibenclamide to insulin treatment is advantageous in NIDDM patients showing secondary failure to OHA. 10-oxohexadecanoic acid 132-135 insulin Homo sapiens 51-58 1314198-1 1992 The aim of this study was to evaluate the insulin (IRI) response to different stimuli and insulin sensitivity in Type 2 diabetic patients responsive to oral hypoglycaemic agents (OHA) and in Type 2 diabetic patients with secondary failure of OHA (SF), all patients being of normal body weight (relative body weight less than 120%), and the possible role of cyclic AMP in the reduced IRI release. 10-oxohexadecanoic acid 179-182 insulin Homo sapiens 42-49 1314198-1 1992 The aim of this study was to evaluate the insulin (IRI) response to different stimuli and insulin sensitivity in Type 2 diabetic patients responsive to oral hypoglycaemic agents (OHA) and in Type 2 diabetic patients with secondary failure of OHA (SF), all patients being of normal body weight (relative body weight less than 120%), and the possible role of cyclic AMP in the reduced IRI release. 10-oxohexadecanoic acid 179-182 insulin Homo sapiens 90-97 29200880-6 2017 Based on the rates of glucose-lowering drug use in Italian patients with diabetes, the annual risk of undergoing a serious hypoglycemic event was estimated at 1.27% for subjects treated with insulin alone, the highest (p<0.00001) as compared with insulin + OHA (0.41%) or OHA alone, either in monotherapy or in multiple therapy (0.1% and 0.17%, respectively). 10-oxohexadecanoic acid 260-263 insulin Homo sapiens 191-198 34648889-3 2021 RESULTS: The French participants treated for type 2 diabetes (T2D) with insulin alone, insulin + oral hypoglycemic agent (OHA) or OHA/GLP-1 analogue were older and presented higher mean values for body mass index, waist circumference and duration of diabetes in years. 10-oxohexadecanoic acid 122-125 insulin Homo sapiens 87-94 32430781-11 2020 Similarly, those who received insulin, with or without OHA, and/or are on diet modification (AOR 1.955, 95% CI 1.243-3.074) were at higher odds of suffering from poor-to-moderate QOL compared to those receiving OHA and/or diet modification. 10-oxohexadecanoic acid 211-214 insulin Homo sapiens 30-37 34496864-8 2021 Insulin therapy combined with OHAs also showed an increased mortality risk (HR = 1.29, 95 % CI 1.14-1.46) compared with the OHA alone group. 10-oxohexadecanoic acid 124-127 insulin Homo sapiens 0-7 29200880-6 2017 Based on the rates of glucose-lowering drug use in Italian patients with diabetes, the annual risk of undergoing a serious hypoglycemic event was estimated at 1.27% for subjects treated with insulin alone, the highest (p<0.00001) as compared with insulin + OHA (0.41%) or OHA alone, either in monotherapy or in multiple therapy (0.1% and 0.17%, respectively). 10-oxohexadecanoic acid 275-278 insulin Homo sapiens 191-198